July 14, 2023 11:51AM 

# Rep. Miller-Meeks’ OTC Act Might Nudge the FDA and Drug Makers Towards Making All Hormonal Contraceptives Over-The-Counter 

By [Jeffrey A. Singer](https://www.cato.org/people/jeffrey-singer) 

---

<a class="js-popover-trigger cursor-pointer popover-trigger" data-bs-placement="bottom" data-bs-trigger="click" id="popover-trigger"> 

SHARE 

</a> 

On the same day that the Food and Drug Administration [allowed](https://www.cato.org/blog/fda-finally-allows-women-otc-access-one-brand-minipill-mini-step-right-direction) women over-the-counter access to one progestin-only birth control pill, Rep. Mariannette Miller-Meeks (R‑Iowa) introduced the [OTC (Orally-Taken Contraceptive) Act](https://www.documentcloud.org/documents/23874210-miller-meeks-otc) in the U.S. House of Representatives. The bill has seven Republican women co-sponsors. Notably, Rep. Miller-Meeks is also a medical doctor. As I have, the American College of Obstetrics and Gynecology, the American Academy of Family Physicians, and the American Medical Association have long supported making all hormonal contraceptives over-the-counter available.

Last session, Miller-Meeks co-sponsored the “[Allowing Greater Access to Safe and Effective Contraception Act,](https://mcusercontent.com/ffedde7e54b71a41a9505fff1/files/4a21d09a-edc1-4cab-79df-43a764fa2778/HINSON_076_xml_SIGNED.pdf)” which instructed the FDA to prioritize contraceptive makers’ applications for over-the-counter status. But the OTC Act goes much further. The bill directs the FDA to provide guidelines to makers of hormonal contraceptives intended to facilitate their application for over-the-counter approval.

The bill’s language appears inspired by how the FDA gradually [nudged](https://www.cato.org/blog/americans-may-finally-get-access-otc-naloxone) Emergent BioSolutions, the makers of *Narcan* naloxone nasal spray, to seek the agency’s [approval](https://www.cato.org/blog/fda-finally-let-people-get-naloxone-without-prescription) for over-the-counter sales. In that case, the FDA told makers of *Narcan*, who could charge high prices to third-party payers for the prescription drug, that the agency was likely to approve a generic competitor for over-the-counter access. The company then sought approval for over-the-counter status. Providing guidelines to hormonal contraceptive manufacturers on how to expedite over-the-counter approval might have a similar effect.

Congress has the authority to order the FDA to reclassify all hormonal contraceptives as over-the-counter by a specific date. But this bill certainly helps move the ball in the right direction.

##### Related Tags 

[Regulation](https://www.cato.org/regulatory-studies), [Health Care](https://www.cato.org/health-care) 

[![Creative Commons License](/build/cato_2020/images/creative-commons.svg)](http://creativecommons.org/licenses/by-nc-sa/4.0/) 
This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/).